517 related articles for article (PubMed ID: 15749129)
1. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Chou TH; Wang S; Sakhatskyy PV; Mboudjeka I; Lawrence JM; Huang S; Coley S; Yang B; Li J; Zhu Q; Lu S
Virology; 2005 Mar; 334(1):134-43. PubMed ID: 15749129
[TBL] [Abstract][Full Text] [Related]
2. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
He Y; Li J; Heck S; Lustigman S; Jiang S
J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
[TBL] [Abstract][Full Text] [Related]
3. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
[TBL] [Abstract][Full Text] [Related]
4. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
van den Brink EN; Ter Meulen J; Cox F; Jongeneelen MA; Thijsse A; Throsby M; Marissen WE; Rood PM; Bakker AB; Gelderblom HR; Martina BE; Osterhaus AD; Preiser W; Doerr HW; de Kruif J; Goudsmit J
J Virol; 2005 Feb; 79(3):1635-44. PubMed ID: 15650189
[TBL] [Abstract][Full Text] [Related]
5. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
Chen Z; Zhang L; Qin C; Ba L; Yi CE; Zhang F; Wei Q; He T; Yu W; Yu J; Gao H; Tu X; Gettie A; Farzan M; Yuen KY; Ho DD
J Virol; 2005 Mar; 79(5):2678-88. PubMed ID: 15708987
[TBL] [Abstract][Full Text] [Related]
6. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins.
Tripp RA; Haynes LM; Moore D; Anderson B; Tamin A; Harcourt BH; Jones LP; Yilla M; Babcock GJ; Greenough T; Ambrosino DM; Alvarez R; Callaway J; Cavitt S; Kamrud K; Alterson H; Smith J; Harcourt JL; Miao C; Razdan R; Comer JA; Rollin PE; Ksiazek TG; Sanchez A; Rota PA; Bellini WJ; Anderson LJ
J Virol Methods; 2005 Sep; 128(1-2):21-8. PubMed ID: 15885812
[TBL] [Abstract][Full Text] [Related]
8. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
He Y; Li J; Du L; Yan X; Hu G; Zhou Y; Jiang S
Vaccine; 2006 Jun; 24(26):5498-508. PubMed ID: 16725238
[TBL] [Abstract][Full Text] [Related]
10. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
[TBL] [Abstract][Full Text] [Related]
12. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
[TBL] [Abstract][Full Text] [Related]
13. Production of a monoclonal antibody against SARS-CoV spike protein with single intrasplenic immunization of plasmid DNA.
Yu XF; Liang LH; She M; Liao XL; Gu J; Li YH; Han ZC
Immunol Lett; 2005 Sep; 100(2):177-81. PubMed ID: 15893826
[TBL] [Abstract][Full Text] [Related]
14. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Du L; Zhao G; He Y; Guo Y; Zheng BJ; Jiang S; Zhou Y
Vaccine; 2007 Apr; 25(15):2832-8. PubMed ID: 17092615
[TBL] [Abstract][Full Text] [Related]
15. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
Faber M; Lamirande EW; Roberts A; Rice AB; Koprowski H; Dietzschold B; Schnell MJ
J Gen Virol; 2005 May; 86(Pt 5):1435-1440. PubMed ID: 15831955
[TBL] [Abstract][Full Text] [Related]
16. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus.
Shih YP; Chen CY; Liu SJ; Chen KH; Lee YM; Chao YC; Chen YM
J Virol; 2006 Nov; 80(21):10315-24. PubMed ID: 17041212
[TBL] [Abstract][Full Text] [Related]
17. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.
Yi CE; Ba L; Zhang L; Ho DD; Chen Z
J Virol; 2005 Sep; 79(18):11638-46. PubMed ID: 16140741
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.
Li J; Ulitzky L; Silberstein E; Taylor DR; Viscidi R
Viral Immunol; 2013 Apr; 26(2):126-32. PubMed ID: 23573979
[TBL] [Abstract][Full Text] [Related]
19. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
He Y; Li J; Li W; Lustigman S; Farzan M; Jiang S
J Immunol; 2006 May; 176(10):6085-92. PubMed ID: 16670317
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
